

| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 60mg | 240 pills | C$1.64 | C$462.21 C$392.88 Best Price | |
| 60mg | 180 pills | C$1.70 | C$360.01 C$306.00 | |
| 60mg | 120 pills | C$1.84 | C$260.13 C$221.11 | |
| 60mg | 90 pills | C$1.93 | C$204.38 C$173.72 | |
| 60mg | 60 pills | C$2.07 | C$146.31 C$124.36 | |
| 60mg | 30 pills | C$2.35 | C$83.60 C$71.06 | |
| 90mg | 240 pills | C$2.55 | C$720.03 C$612.03 | |
| 90mg | 180 pills | C$2.59 | C$548.15 C$465.93 | |
| 90mg | 120 pills | C$2.65 | C$373.94 C$317.85 | |
| 90mg | 90 pills | C$2.76 | C$292.65 C$248.75 | |
| 90mg | 60 pills | C$2.90 | C$204.38 C$173.72 | |
| 90mg | 30 pills | C$3.12 | C$109.15 C$92.77 | |
| 120mg | 240 pills | C$2.96 | C$836.17 C$710.75 Popular | |
| 120mg | 180 pills | C$3.02 | C$638.74 C$542.93 | |
| 120mg | 120 pills | C$3.08 | C$434.33 C$369.18 | |
| 120mg | 90 pills | C$3.24 | C$343.75 C$292.18 | |
| 120mg | 60 pills | C$3.40 | C$239.22 C$203.34 | |
| 120mg | 30 pills | C$3.63 | C$127.73 C$108.57 |
Disclaimer: This information is intended for adults in Canada and should not replace professional medical advice. Consult a pharmacist or physician for individual guidance about Arcoxia.
Arcoxia is the brand name for etoricoxib, a medicine that belongs to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It is a COX-2 selective NSAID, which means it preferentially blocks the cyclooxygenase-2 enzyme involved in inflammation and pain.
Active ingredient: etoricoxib. Drug class: COX-2 selective NSAID. Basic purpose: to reduce inflammation, swelling and pain in conditions affecting joints and surrounding tissues by decreasing the production of prostaglandins at sites of tissue injury or inflammation.
The medicine is used to relieve symptoms such as pain and stiffness that accompany inflammatory disorders of the musculoskeletal system. The goal is to improve daily function and the ability to move more comfortably. The exact indication depends on local regulatory rules and medical judgment; the official patient information leaflet should be consulted for specific permitted uses.
Arcoxia is available in tablet form and is prescribed by a clinician. The duration of therapy and the dose will be determined by a healthcare professional based on the condition, age, kidney and liver function, and response to treatment. Check the official leaflet or consult a healthcare professional for specifics about appropriate use.
Arcoxia is used to address pain and inflammation associated with certain degenerative or inflammatory joint diseases. The conditions most commonly considered include osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, where morning stiffness and persistent joint pain can limit activity.
Typical symptoms include joint tenderness, swelling, reduced range of motion, and difficulty performing ordinary tasks such as standing from a seated position or climbing stairs. Pain may be present at rest or with activity, and stiffness can be most noticeable after periods of inactivity.
In some patients, Arcoxia may be prescribed for short-term relief of acute pain caused by dental procedures or minor surgery, when clinically appropriate. The decision to use Arcoxia for acute pain takes into account the expected duration of pain and the individual risk profile.
The exact approved indications may vary by jurisdiction and over time. Always refer to the official product labeling and obtain guidance from a prescriber or pharmacist to confirm whether a given indication is appropriate for the patient’s situation.
Etoricoxib inhibits the COX-2 enzyme, a catalyst for the formation of prostaglandins in inflamed tissues. Prostaglandins contribute to pain, swelling, and redness in areas of tissue injury or inflammatory disease.
By reducing the production of prostaglandins, Arcoxia decreases inflammation and associated pain. The effect tends to improve joint comfort and mobility, enabling more normal activity and participation in daily tasks.
The drug’s COX-2 selectivity aims to spare some of the protective functions of the COX-1 enzyme, which is involved in protecting the stomach lining and supporting normal kidney function. While this selectivity can lower certain gastrointestinal risks relative to nonselective NSAIDs, GI adverse effects and other risks may still occur.
Systemically, the action may influence blood pressure, kidney function, and liver enzymes in some individuals, particularly with longer-term use or higher doses. Ongoing monitoring and periodic assessment by a clinician help ensure safety during extended therapy.
Arcoxia should be taken exactly as prescribed by a healthcare professional. The choice of dose and the duration of therapy depend on the medical condition, patient age, kidney function, liver function, and response to treatment. Do not alter the prescribed plan without medical advice.
Tablets are to be swallowed whole with a full glass of water. Do not crush, chews, or break the tablet unless specifically instructed by the prescriber or the product labeling, as altering the tablet can change the way the medication is absorbed.
Timing and frequency vary according to the condition being treated. Some regimens involve once-daily dosing, while others may use different schedules. Arcoxia can be taken with or without food; taking it with meals may help minimize stomach upset in some individuals.
If a dose is missed, follow the guidance provided by the clinician or the information on the patient leaflet. In general, do not double the next dose to make up for a missed one. If unsure, contact a pharmacist or prescriber for specific instructions before resuming the regimen. Do not continue beyond the prescribed duration without clinical oversight.
Arcoxia should not be used by individuals with known allergy to etoricoxib, other COX-2 inhibitors, or any ingredient in the tablet formulation. An immediate discontinuation and medical evaluation are advised if signs of an allergic reaction occur after taking the medicine.
Contraindications include active peptic ulcers or a history of serious gastrointestinal bleeding, perforation, or ulceration, and known significant bleeding disorders. A clinician will assess individual risk before starting therapy.
Severe heart failure, significant kidney impairment, or severe liver impairment increases risk with NSAID therapy and may preclude use. Uncontrolled hypertension or a history of ischemic heart disease or stroke requires careful consideration by a prescriber.
In pregnant individuals, especially during the third trimester, or in those who are breastfeeding, Arcoxia is typically avoided unless the clinician determines that potential benefits outweigh risks. Local guidelines and the official leaflet should be consulted for pregnancy and lactation considerations.
Cardiovascular risk: Arcoxia may be associated with an increased risk of heart attack or stroke, particularly with long-term use or higher doses. A history of cardiovascular disease requires careful risk assessment by a clinician before initiating therapy.
Gastrointestinal risk: NSAIDs can cause ulcers, bleeding, or perforation of the stomach or intestines. The risk is higher in older adults or in those with a prior history of GI disease. The possibility of GI adverse events should be weighed against potential benefits during treatment planning.
Kidney and liver function: Kidney function can be affected, especially in individuals with preexisting kidney disease or dehydration. Liver enzymes may be temporarily elevated in some patients; periodic monitoring may be indicated for ongoing therapy.
Allergic reactions and skin effects: Severe allergic reactions and rare but serious skin reactions can occur. Prompt medical attention is required if signs such as widespread rash, blistering, or swelling appear. Seek urgent medical help if symptoms escalate rapidly.
Common adverse effects include abdominal discomfort, indigestion, heartburn, nausea, dizziness, and headaches. These are typically mild and may improve with continued therapy or with reassurance from a clinician.
Other possible effects include swelling of the hands or feet, high blood pressure, or mild liver enzyme increases detected on routine testing. If any of these persist or worsen, a clinician should be informed.
Serious but uncommon reactions can include signs of gastrointestinal bleeding (such as black or tarry stools, vomiting blood), chest pain suggesting a heart problem, shortness of breath, severe allergic reactions, or persistent severe rash. Any of these warrant immediate medical evaluation.
Most adverse effects are manageable with medical supervision. If new or unusual symptoms occur after starting therapy, contact a healthcare professional for assessment and guidance.
Interactions with other medicines can alter the effectiveness of Arcoxia or increase the risk of adverse effects. A thorough medication history helps identify potential interactions before starting therapy.
Concomitant use with other NSAIDs, aspirin, anticoagulants, or corticosteroids can raise the risk of GI bleeding or kidney effects. Careful consideration and supervision are required when combining these therapies.
Medications that affect blood pressure, kidney function, or liver enzymes may interact with Arcoxia. When used with diuretics, ACE inhibitors, or ARBs, kidney function should be monitored and dose adjustments may be necessary.
Herbal supplements and over‑the‑counter products can also interact with Arcoxia. Inform the pharmacist about all substances being taken, including vitamins and herbal products, to avoid unforeseen interactions. If there is any doubt, consult a clinician before making changes to the regimen.
During pregnancy, Arcoxia is generally not recommended unless explicitly advised by a clinician after a careful benefit–risk assessment. The potential impact on fetal development and pregnancy outcomes requires professional input before use.
Use in the third trimester is typically contraindicated due to potential harm to the fetus and complications during delivery. If pregnancy occurs or is planned, consult a healthcare professional promptly to discuss alternatives or adjustments to therapy.
Breastfeeding is not routinely advised while taking Arcoxia, since the drug may pass into breast milk. A clinician can provide guidance on whether a safe alternative is available or whether to discontinue breastfeeding during treatment.
For anyone considering Arcoxia while pregnant or breastfeeding, the decision should involve a careful discussion with a prescriber or pharmacist, taking into account all medical conditions and current therapies. If planning pregnancy, consult a healthcare professional about suitable pain management options.
Most people begin treatment with information provided by the prescribing clinician and the official patient information leaflet. Time to onset of relief, duration of therapy, and monitoring plans vary by individual circumstances and medical history. A pharmacist can help interpret the label and answer questions about the plan.
The following questions reflect common concerns. If any item remains unclear, consult a healthcare professional for personalized guidance before making changes to therapy.
Questions in this section are intended to be practical and cautious rather than prescriptive about dosing. Always follow the instructions given by a clinician or in the official leaflet.
In all cases, if severe symptoms or signs of an adverse reaction occur, seek medical help promptly and contact a healthcare professional for further instructions tailored to the situation.
Time to noticeable relief varies among individuals. Some may notice improvement within hours, while others may require several days of treatment. The overall response depends on the condition being treated and the response to the medication.
Take the missed dose as soon as remembered if it is within the same day. If it is nearly time for the next dose, skip the missed dose and resume the regular schedule. Do not double the next dose to make up for the missed one. If unsure, contact a pharmacist or prescriber for specific guidance.
Moderation is advised. Alcohol can irritate the stomach and may increase the risk of GI side effects when taking NSAIDs. Discuss alcohol use with a clinician if a medication plan is in place, particularly for longer courses or higher doses.
The duration of therapy is determined by the prescriber based on the clinical indication and patient risk factors. Regular review is recommended to reassess need, effectiveness, and safety, especially for ongoing long-term use.
Concomitant use with other NSAIDs or aspirin can increase the risk of GI irritation or bleeding and renal effects. A clinician should evaluate any combination of pain medicines to ensure safety and optimal pain control.
Kidney function can influence the safety profile of NSAIDs. In individuals with existing kidney disease or reduced kidney function, a clinician may adjust the dose, monitor function, or choose an alternative therapy. Do not initiate changes without medical advice.
Age can increase susceptibility to adverse effects, including GI, cardiovascular, and renal events. A clinician may recommend closer monitoring, dose adjustments, or alternative therapies based on overall health and coexisting conditions.
Seek urgent medical help if any of the following occur after taking Arcoxia: swelling of the face or throat, severe rash with blisters, shortness of breath, chest tightness, or dizziness. Stop the medication and obtain care promptly if an allergic reaction is suspected.
Food can influence the rate of absorption and the timing of relief in some individuals. Taking Arcoxia with meals may reduce stomach upset, but onset of action may be slightly delayed in some cases. Discuss personal tolerability with a clinician.
Use during pregnancy, particularly in the first trimester and beyond, requires careful assessment by a clinician or pharmacist. The potential risks to the fetus must be weighed against the benefits of pain relief. An alternative therapy may be recommended if pregnancy is planned or confirmed.
Consult a clinician before stopping the medication, especially for long-term use. A gradual reduction or tapering plan may be advised to minimize the risk of recurrence of symptoms or other issues.
Additional information is available in the official patient information leaflet that accompanies the medicine. Healthcare professionals, including pharmacists and prescribers, can provide personalized guidance and answer questions about individual health circumstances. Manufacturer resources and Health Canada labeling may also offer detailed safety and usage information, but professional consultation remains essential for personal medical decisions.
The official patient information leaflet (PIL) provided with Arcoxia contains detailed instructions on dosing, contraindications, warnings, and side effects. It should be read carefully before starting therapy and kept for reference during treatment.
Professionals such as pharmacists and prescribers can clarify any questions about how Arcoxia fits into an individual treatment plan. They can explain how the medicine interacts with other medications, foods, or supplements and help adjust therapy if adverse effects or changes in health occur.
Health Canada and the product’s manufacturer publish labeling, safety information and guidance for clinicians and patients. These sources are intended to support safe use and informed decision-making, in conjunction with the clinical judgment of a healthcare professional.
When in doubt about Arcoxia or its use, seek advice from a pharmacist or physician. If symptoms persist, worsen, or new health concerns arise during treatment, contact a healthcare professional promptly for assessment and management tailored to the individual’s health status.
14–21 days. Free from C$282.05 .
5–9 days. C$42.31
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
